相似文献
1
No change in small low-density lipoprotein cholesterol levels with pemafibrate might explain the negative results of the PROMINENT trial.
J Diabetes Investig. 2023 Apr;14(4):630-631. doi: 10.1111/jdi.13983. Epub 2023 Jan 27.
2
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5.
3
Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet.
Cardiovasc Diabetol. 2020 Sep 26;19(1):149. doi: 10.1186/s12933-020-01132-2.
4
Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia.
J Clin Lipidol. 2018 Sep-Oct;12(5):1267-1279.e4. doi: 10.1016/j.jacl.2018.06.010. Epub 2018 Jun 26.
5
The effect of fenofibrate on insulin sensitivity and plasma lipid profile in non-diabetic males with low high density lipoprotein/dyslipidaemic syndrome.
Ann Acad Med Singap. 1999 Nov;28(6):778-82.
6
Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
J Atheroscler Thromb. 2018 Jun 1;25(6):521-538. doi: 10.5551/jat.44412. Epub 2018 Apr 7.
7
Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
Ann Intern Med. 1996 Oct 1;125(7):529-40. doi: 10.7326/0003-4819-125-7-199610010-00001.
8
Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
Metabolism. 2008 Jun;57(6):796-801. doi: 10.1016/j.metabol.2008.01.026.
9
Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes.
Metabolism. 2005 Feb;54(2):227-34. doi: 10.1016/j.metabol.2004.08.017.
10
The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
Metabolism. 2013 Dec;62(12):1840-9. doi: 10.1016/j.metabol.2013.08.001. Epub 2013 Sep 13.
引用本文的文献
1
Effects of Pemafibrate on Cardio-Ankle Vascular Index (CAVI) in Patients with Type 2 Diabetes or Ischemic Heart Disease: A 24-Week Observational Study.
Vasc Health Risk Manag. 2025 Apr 24;21:293-304. doi: 10.2147/VHRM.S506642. eCollection 2025.
2
Clinical significance of small dense low-density lipoprotein cholesterol measurement in type 2 diabetes.
J Diabetes Investig. 2025 Mar;16(3):370-383. doi: 10.1111/jdi.14398. Epub 2025 Jan 7.
3
Lessons from PROMINENT and prospects for pemafibrate.
Cardiovasc Diabetol. 2024 Jul 29;23(1):279. doi: 10.1186/s12933-024-02305-z.
4
The chylomicron saga: time to focus on postprandial metabolism.
Front Endocrinol (Lausanne). 2024 Jan 18;14:1322869. doi: 10.3389/fendo.2023.1322869. eCollection 2023.
5
Prospective randomized comparative study of the effect of pemafibrate add-on or double statin dose on small dense low-density lipoprotein-cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy.
J Diabetes Investig. 2023 Dec;14(12):1401-1411. doi: 10.1111/jdi.14076. Epub 2023 Aug 30.
6
Hypertriglyceridemia contributes significantly to high prevalence of small dense LDL-cholesterol in patients with type 2 diabetes, even when LDL-C targets are achieved.
Diabetol Int. 2023 May 15;14(3):288-293. doi: 10.1007/s13340-023-00634-0. eCollection 2023 Jul.
7
Dietary Effects on Monocyte Phenotypes in Subjects With Hypertriglyceridemia and Metabolic Syndrome.
JACC Basic Transl Sci. 2023 Apr 26;8(5):460-475. doi: 10.1016/j.jacbts.2023.02.011. eCollection 2023 May.
8
The influence of triglycerides on small dense low-density lipoprotein cholesterol levels is attenuated in low low-density lipoprotein-cholesterol range: Implications for the negative results of the PROMINENT trial.
J Diabetes Investig. 2023 Jul;14(7):902-906. doi: 10.1111/jdi.14013. Epub 2023 Apr 4.
本文引用的文献
1
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5.
2
A New Equation Based on the Standard Lipid Panel for Calculating Small Dense Low-Density Lipoprotein-Cholesterol and Its Use as a Risk-Enhancer Test.
Clin Chem. 2021 Jul 6;67(7):987-997. doi: 10.1093/clinchem/hvab048.
3
Detailed analysis of lipolytic enzymes in a Japanese woman of familial lipoprotein lipase deficiency - Effects of pemafibrate treatment.
Clin Chim Acta. 2020 Nov;510:216-219. doi: 10.1016/j.cca.2020.07.031. Epub 2020 Jul 17.
4
Development of a homogeneous assay for measurement of small dense LDL cholesterol.
Clin Chem. 2011 Jan;57(1):57-65. doi: 10.1373/clinchem.2010.149559. Epub 2010 Nov 4.
Zotero 插件